# Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

> **NCT04170023** · PHASE2 · TERMINATED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** ALXN2050

## Key facts

- **NCT ID:** NCT04170023
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-16
- **Primary completion:** 2023-04-27
- **Final completion:** 2024-03-20
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Did not appropriately control IVH; significantly increased rates of BTH and LDH excursions (LDH excursions is defined by LDH values \> X2ULN) compared to ravulizumab.
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04170023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04170023, "Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04170023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*